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Lipoproteins and AtherosclerosisChristopher K. Glass*†‡ and Joseph L. Witztum*
Specialized Center of Research on Molecular Serum cholesterol is carried by several lipoprotein parti-
Medicine and Atherosclerosis cles that perform the complex physiologic tasks of
*Department of Medicine transporting dietary and endogenously produced lipids
Division of Endocrinology and Metabolism (reviewed in Witztum and Steinberg, 1995). Chylomicrons
†Department of Cellular and Molecular Medicine provide the primary means of transport of dietary lipids,
University of California, San Diego while very low density lipoproteins (VLDL), low density
9500 Gilman Drive lipoproteins (LDL), and high density lipoproteins (HDL)
La Jolla, California 92093 function to transport endogenous lipids. Triglyceride-
rich VLDL particles containing apolipoprotein B-100
(apo B-100) and apolipoprotein E (apo E) are synthesized
by the liver and function to transport fatty acids to adi-Complications of atherosclerosis are the most common
pose tissue and muscle. After triglyceride removal incauses of death in Western societies. In broad outline,
peripheral tissues, a portion of the remaining VLDL rem-atherosclerosis can be considered to be a form of
nants are metabolized to LDL particles by further re-chronic inflammation resulting from interaction between
moval of core triglycerides and dissociation of apolipo-modified lipoproteins, monocyte-derived macrophages,
proteins other than apo B-100. In humans, the majorityT cells, and the normal cellular elements of the arterial
of serum cholesterol is carried by LDL particles.wall. This inflammatory process can ultimately lead to
While LDL has an essential physiological role as athe development of complex lesions, or plaques, that
vehicle for the delivery of cholesterol to peripheral tis-protrude into the arterial lumen. Plaque rupture and
sues, increased LDL cholesterol levels are associatedthrombosis results in the acute clinical complications of
with increased risk of cardiovascular disease. LDL ismyocardial infarction and stroke (Navab et al., 1996;
taken up by cells via LDL receptors that recognize anRoss, 1999; Steinberg and Witztum, 1999). Among the
N-terminal domain of apo B-100. The circulating levelmany genetic and environmental risk factors that have
of LDL is determined in large part by its rate of uptakebeen identified by epidemiologic studies (Table 1), ele-
vated levels of serum cholesterol are probably unique through the hepatic LDL receptor pathway, as evi-
in being sufficient to drive the development of athero- denced by the fact that lack of functional LDL receptors
sclerosis in humans and experimental animals, even in is responsible for the massive accumulation of LDL in
the absence of other known risk factors. The elucidation patients with homozygous familial hypercholesterol-
of molecular mechanisms that control cholesterol bio- emia (Goldstein and Brown, 1977). The expression of
synthesis and serum cholesterol levels (reviewed in LDL receptors is subject to feedback control by intracel-
Goldstein and Brown, 1977) led to the development of lular cholesterol levels. Low levels of intracellular choles-
“statins,” a potent class of cholesterol lowering drugs terol lead to activation of the SREBP transcription fac-
that have been proven to significantly reduce cardiovas- tors, which stimulate transcription of the LDL receptor
cular mortality in hypercholesterolemic patients (Gould gene and other genes involved in cholesterol biosyn-
et al., 1998). However, available statins are not sufficient thesis (Brown and Goldstein, 1997). Statins lower circu-
to fully prevent the progression of atherosclerosis in lating cholesterol levels indirectly by inhibiting HMG
many susceptible individuals. Indeed, even among indi- CoA-reductase, the rate limiting enzyme required for
viduals with the same cholesterol levels there is great endogenous cholesterol biosynthesis. The resulting de-
disparity in the expression of clinical disease. This is crease in intracellular cholesterol leads to activation of
most vividly illustrated by two subjects with the same SREBP, upregulation of LDL receptors, and enhanced
founder gene defect leading to homozygous familial hy- clearance from plasma degradation of LDL, reducing its
percholesterolemia, and similarly elevated plasma cho- circulating levels.
lesterol levels. One, a male, died of coronary artery dis- Targeted disruption of the apo E or LDL receptor
ease at age 3, while a female, despite developing genes, or overexpression of the human apo B gene in
symptoms of cardiovascular disease, died of unrelated mice, results in marked increases in VLDL and/or LDL
causes at age 33 (Hobbs et al., 1990). Thus, an under- cholesterol levels. When such animals are fed high cho-
standing of other factors contributing to atherogenesis lesterol diets, plasma cholesterol levels are greatly exag-
is needed to develop new strategies for prevention and gerated and reach values in excess of 1500–2000 mg/
treatment. Here, we review recent studies of molecular dl (Smithies and Maeda, 1995; Breslow, 1996). Although
mechanisms underlying the pathogenesis of atheroscle-
mice are normally very resistant to the development of
rosis and provide examples of how emerging technolo-
atherosclerosis, the combination of these genetic and
gies may be used to accelerate the pace of discovery
dietary manipulations results in massive hypercholes-
and facilitate development of novel therapeutic ap-
terolemia leading to extensive atherosclerotic diseaseproaches.
that occurs throughout the aorta and has many features
in common with human lesions. The development of
murine models of atherosclerosis has revolutionized the‡ To whom correspondence should be addressed (e-mail: cglass@
ucsd.edu). approach to evaluating potential roles of specific pro-
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over a time scale of weeks to months. In contrast, theTable 1. Risk Factors for Development of Atherosclerosis
development of atherosclerosis in humans evolves over
Factors with a Significant Genetic Component
decades and advanced lesions are typically less cellular
Elevated levels of LDL and VLDL than those observed in animal models. Furthermore,
Low levels of HDL thrombotic events that account for myocardial infarction
Elevated lipoprotein (a)
in humans have not been consistently observed in mice.Hypertension
In spite of these caveats, genetic studies in mice provideDiabetes Mellitus
the most powerful approach available to validate rolesMale gender
Elevated levels of homocysteine of candidate genes in vivo.
Elevated levels of hemostatic factors, e.g., fibrinogen
Metabolic syndrome
Initiating Events; LDL ModificationInsulin resistance
Atherosclerotic lesions begin as fatty streaks underlyingObesity
the endothelium of large arteries (Figures 1A and 2).Family history
Environmental Factors Recruitment of macrophages and their subsequent up-
take of LDL-derived cholesterol are the major cellularSmoking
events contributing to fatty streak formation. Many linesLack of exercise
High fat diet of evidence suggest that oxidative modifications in the
Infectious agents lipid and apolipoprotein B (apo B) components of LDL
drive the initial formation of fatty streaks (Navab et al.,
1996; Steinberg and Witztum, 1999). Indeed immuno-
logic evidence of LDL oxidation is observed even inteins in lesion development. The crossing of these ani-
mals with mice that have been engineered to overex- human fetal arteries prior to the presence of macro-
phages (Napoli et al., 1997). The specific properties ofpress or lack genes of interest has led to a growing list
of proteins that accelerate or retard the rate at which oxidized LDL (oxLDL), usually studied following oxida-
tion of native LDL in vitro, depend on the extent oflesions develop, and/or alter lesion composition, exam-
ples of which are provided in Table 2 and described modification. This can range from “minimal” modifica-
tion, (mmLDL) in which the LDL particle can still bethroughout this review. The products encoded by these
genes thus represent potential targets for therapeutic recognized by LDL receptors (Navab et al., 1996), to
extensive oxidation, in which the apo B component isintervention in humans. It is important to note that the
development of atherosclerosis in these murine models, fragmented and lysine residues are covalently modified
with reactive breakdown products of oxidized lipidsas in virtually all animal models of atherosclerosis, is
driven by extreme elevations in circulating cholesterol (Steinberg and Witztum, 1999). Such particles are not
bound by the LDL receptor, but rather by several so-levels that result in the formation of extensive lesions
Table 2. Examples of Genes that Influence Development of Atherosclerosis in Hypercholesterolemia Mice
Genetic Effects on
Gene Experiment Background Lesion Area Proposed Mechanism Reference
Atherogenic Genes
12/15-LO Knockout apoE2/2 ## Decreased LDL oxidation Cyprus et al., 1999;
Overexpression LDL R2/2 " Increased LDL oxidation Harats et al., 2000
Detmer et al., 2000;
iNOS Knockout apoE2/2 # Decreased LDL oxidation Behr-Roussel et al., 2000
M-CSF Knockout apoE2/2 ## Decreased macrophage infiltration Smith et al., 1995;
Qiao et al., 1997
MCP-1 Knockout LDL R2/2 ## Decreased macrophage infiltration Gu et al., 1999;
apoE2/2 Gosling et al., 1999
CCR2 Knockout apoE2/2 ## Decreased macrophage infiltration Boring et al., 1998
P- and E-selectin Combined knockout LDL R2/2 # Decreased monocyte adherence Dong et al., 1998
CXCR-2 Knockout LDL R2/2 # Decreased macrophage residence Boisvert et al., 1998
SR-A Knockout apoE2/2 # Decreased uptake of oxLDL Suzuki et al., 1997
CD36 Knockout apoE2/2 ## Decreased uptake of oxLDL Febraio et al., 2000
IFNg receptor (R0) Knockout apoE2/2 # Decreased inflammatory responses, Gupta et al., 1997
increased apoAIV
CD154 Knockout apoE2/2 # Decreased CD40 signaling Lutgens et al., 1999
IL-10 Knockout C57 BL/6J " Increased inflammatory responses Pinderski et al., 1999;
Mallat et al., 1999
Antiatherogenic Genes
Paraoxinase Knockout apoE2/2 " Reduced clearance of oxidized lipids Shih et al., 2000
apo A-I Knockout h apoB transgene " Decreased reverse cholesterol transport Voyaziakis et al., 1998
Overexpression apo E2/2 # Increased reverse cholesterol transport Benoit et al., 1999;
LDL R2/2 Tangirala et al., 1999
PPARg Knockout LDL R2/2 " Altered macrophage function Chawla et al., 2001;
Agonist LDL R2/2 # Lie et al., 2000
SR-B1 Knockout LDL R2/2 " Decreased reverse cholesterol transport Huszar et al., 2000
Overexpression LDL R2/2 # Increased reverse cholesterol transport Kozavsky et al., 2000
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A number of potential oxidant-generating systems
have been investigated that could directly or indirectly
target LDL lipids, including myeloperoxidase, nitric ox-
ide synthase and 15-lipoxygenase (15-LO) (Heinecke,
1998; Steinberg and Witztum, 1999). Recent evidence
supporting a proatherogenic role of 15-LO has been
obtained by knocking out the homologous leukocyte 12/
15-LO gene in mice and crossing these animals with
apo E–deficient mice (Cyrus et al., 1999). Double knock-
out mice exhibited a striking reduction in atherosclerosis
as compared to apo E–deficient control animals, con-
firming a role of 15-LO as a disease-modifying enzyme.
Consistent with this, overexpression of 15-LO in the
vessel wall of LDL receptor–deficient mice led to accel-
erated development of atherosclerosis (Harats et al.,
2000).
Nitric oxide (NO) is a potent oxidant produced by both
endothelial cells and macrophages that appears to exert
both atherogenic and protective effects, dependent on
its source of production. The vasodilator function of NO
produced by endothelial NO synthase (eNOS) is protec-
tive, as deletion of the eNOS gene in the background of
apo E deficiency results in hypertension and increased
atherosclerosis (Knowles et al., 2000). In contrast, NO
produced via the much higher capacity inducible NO
synthase (iNOS) in macrophages serves antimicrobial
functions based on its potent oxidative properties. Evi-
dence that inducible nitric oxide synthase contributes
to LDL oxidation in vivo has recently been provided by
studies demonstrating that apo E–deficient mice lacking
iNOS develop less atherosclerosis (although this wasFigure 1. Early and Late Atherosclerotic Lesions
not observed by Knowles et al., 2000) and that inhibitors(A) Cross section of a fatty streak lesion from the aorta of a choles-
of iNOS decrease atherosclerosis in rabbits (Behr-Rous-terol-fed rabbit immunostained for a macrophage-specific marker.
(Micrograph courtesy of Wulf Palinski.) (B) Cross section through a sel et al., 2000; Detmers et al., 2000). In contrast, disrup-
human coronary artery at the level of a thrombotic atherosclerotic tion of the gene encoding gp91-phox required for
lesion causing fatal myocardial infarction. phagocyte NADPH oxidase activity, another potential
contributor to LDL oxidation, did not reduce the devel-
opment of atherosclerosis (Kirk et al., 2000). Degrada-called scavenger receptors expressed on macrophages
tion of biologically active lipids within oxLDL also ap-and smooth muscle cells. While LDL is protected from
pears to determine atherosclerosis susceptibility, asoxidation in the plasma compartment, it is thought to
disruption of the gene encoding serum paraoxonase,become susceptible to enzymatic and nonenzymatic
an esterase/peroxidase carried on HDL that degradesmodifications when retained by extracellular matrix pro-
oxidized phospholipids, resulted in increased lesion de-teins in the artery wall (Schwenke and Carew, 1989;
velopment (Shih et al., 2000).Williams and Tabas, 1998). A large number of proinflam-
matory and proatherogenic properties have been as-
cribed to mmLDL and OxLDL and their components Monocyte/Macrophage Recruitment
Although the recruitment of monocytes to the arterial(Table 3).
There is substantial evidence that LDL oxidation oc- wall and their subsequent differentiation into macro-
phages may initially serve a protective function by re-curs in both animals and in man, and numerous studies
have shown that antioxidant treatment with various moving cytotoxic and proinflammatory oxLDL particles
or apoptotic cells, progressive accumulation of macro-agents reduces the development of atherosclerosis in
both nonprimate and primate hypercholesterolemic ani- phages and their uptake of oxLDL ultimately leads to
development of atherosclerotic lesions. The osteopet-mal models (Steinberg and Witztum, 1999). Epidemio-
logic data in humans also supports a protective role for rotic (op) mouse, which carries a naturally occurring
mutation in the gene encoding macrophage colony stim-antioxidant supplementation (Jha et al., 1995). Despite
this, prospective clinical trials with antioxidant vitamins, ulating factor (M-CSF) and exhibits a near complete
absence of macrophages, is extremely resistant to thesuch as vitamin E and beta carotene, in patients with
preexisting atherosclerosis have thus far been disap- development of atherosclerosis when bred to apo E–defi-
cient mice despite an increase in circulating cholesterolpointing (Yusuf et al., 2000). Pinpointing the molecular
mechanisms responsible for LDL oxidation in vivo and levels (Smith et al., 1995; Qiao et al., 1997).
The recruitment of monocytes to lesion-prone sitesdefining the most susceptible patient populations will
be necessary for the development of specific and effica- of large arteries is regulated by cell adhesion molecules
that are expressed on the surface of endothelial cellscious approaches to antioxidant therapy.
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Figure 2. Initiating Events in the Development of a Fatty Streak Lesion
LDL is subject to oxidative modifications in the subendothelial space, progressing from minimally modified LDL (mmLDL), to extensively
oxidized LDL (oxLDL). Monocytes attach to endothelial cells that have been induced to express cell adhesion molecules by mmLDL and
inflammatory cytokines. Adherent monocytes migrate into the subendothelial space and differentiate into macrophages. Uptake of oxLDL via
scavenger receptors leads to foam cell formation. OxLDL cholesterol taken up by scavenger receptors is subject to esterification and storage in
lipid droplets, is converted to more soluble forms, or is exported to extracellular HDL acceptors via cholesterol transporters, such as ABC-A1.
in response to inflammatory stimuli (Figure 3). Several by the fact that systemic deletion of the VCAM-1 gene
results in early embyronic lethality. E selectin and Pcell adhesion molecules have been suggested to play
roles in macrophage recruitment. One of the first to be selectin appear to play quantitative roles in monocyte
entry based on a 40% to 60% decrease in atherosclero-implicated was VCAM-1, based on its increased expres-
sion on endothelial cells over lesion-prone areas, its sis in apo E–deficient mice lacking both genes (Dong et
al., 1998). Similarly, gene deletion of ICAM-1 resulted inpreferential recruitment of monocytes, and its pattern
of regulation by proinflammatory stimuli (Cybulsky and small but significant reductions in monocyte recruitment
to atherosclerotic lesions in apo E–deficient mice (Col-Gimbrone, 1991). Studies to confirm a role of VCAM-1
in atherosclerosis in the mouse have been complicated lins et al., 2000). Chronic delivery of a peptidomimetic
Table 3. Possible Mechanisms by which oxLDL Components Can Exert Proatherogenic Effects
oxLDL Components(s) Effect Mechanism
lyso phosphatidyl choline (PC), Increased monocyte adhesion Increased expression of adhesion molecules
oxidized phospholipids on endothelial cells
lyso PC, oxidized phospholipids Increased monocyte and T cell chemo- Direct effects on monocytes and T cells and
taxis indirect effects due to stimulation of che-
mokine production (e.g., MCP-1)
lyso PC, oxidized phospholipids Increased scavenger receptor A Activation of AP-1 and ets transcription
expression factors
9-hydroxyeicosatetraenoic acid Increased CD 36 expression Activation of PPARg
Modified apo B and oxidized phos- Increased foam cell formation Enhanced uptake of oxLDL mediated by
pholipids scavenger receptor
lyso PC, oxidized phospholipids Induction of proinflammatory genes Activation of NFkB, AP-1, and increased
cAMP
Oxidized lipids and apo B adducts Induces cellular and humoral immune Neoepitope formation
responses
lyso PC, cholesterol, oxysterols Increased apoptosis and necrosis Activation of programmed cell death, forma-
tion of cholesterol crystals. Loss of mem-
brane integrity




Figure 3. Lesion Progression
Interactions between macrophage foam cells, Th1 and Th2 cells establish a chronic inflammatory process. Cytokines secreted by lymphocytes
and macrophages exert both pro- and antiatherogenic effects on each of the cellular elements of the vessel wall. Smooth muscle cells migrate
from the medial portion of the arterial wall, proliferate and secrete extracellular matrix proteins that form a fibrous plaque.
corresponding to connecting segment 1 (CS-1) domain erosclerosis than mice reconstituted with wild-type
bone marrow cells (Boisvert et al., 1998). In concert,of fibrinectin 1, which blocks function of the adhesion
molecule VLA-4 on the leukocyte surface, reduced lipid these findings suggest that inhibition of macrophage
chemotaxis mediated by MCP-1 and/or interferenceaccumulation in C57BL/6J mice fed an atherogenic diet
(Shih et al., 1999). Together, these findings suggest that with CXCR-2 activity may be of therapeutic benefit.
many cell adhesion molecules contribute to the recruit-
ment of monocytes and T cells to the atherosclerotic Foam Cell Formation
The development of macrophage “foam cells” that con-lesion. Neutrophils, which normally contribute to most
inflammatory responses, are notably absent in lesions, tain massive amounts of cholesterol esters is a hallmark
of both early and late atherosclerotic lesions. Choles-although the mechanisms leading to their exclusion re-
main to be defined. terol accumulation in these cells is thought to be medi-
ated primarily by uptake of modified forms of LDL viaMigration of monocytes into the artery wall is likely
to be stimulated in part by oxLDL, which can directly so-called scavenger receptors (Yamada et al., 1998)
(Figure 2). Recognition of oxLDL by scavenger receptorsattract monocytes (Steinberg et al., 1989) and can also
induce the expression of chemotactic molecules by en- is mediated, at least in part by oxidized phospholipids
in both the lipid phase and as covalent adducts on apodothelial cells, such as monocyte chemotactic protein
1 (MCP-1) (Navab et al., 1996). Intriguingly, monocyte B (Ho¨rkko¨ et al., 2000). Although several proteins may
contribute to this overall process, scavenger receptorsexpression of CCR2, the receptor for MCP-1, is stimu-
lated by hypercholesterolemia and monocytes derived A (SR-A) and CD36 have been demonstrated to play
quantitatively significant roles. Apo E–deficient micefrom hypercholesterolemic patients exhibit increased
chemotactic responses to MCP-1 (Han et al., 1999). Dis- lacking the SR-A or CD36 scavenger receptors devel-
oped significantly less atherosclerosis than control aporuption of the MCP-1 or CCR2 genes markedly reduces
the development of atherosclerosis in apoE2/2 or apo E–deficient mice, with quantitatively greater reductions
in lesion area observed in CD36/apo E–deficient miceB–overexpressing mice, respectively (Boring et al., 1998;
Gu et al., 1998; Gosling et al., 1999). IL-8, which is pres- (Suzuki et al., 1997; Febraio et al., 2000).
OxLDL-derived cholesterol brought into the macro-ent in human atherosclerosis lesions, may also play a
role in monocyte-macrophage trafficking. Although a phage via scavenger receptors consists of free choles-
terol as well as cholesterol esters that are hydrolyzedclear homolog of IL-8 has not been established in the
mouse, reconstitution of the hematopoietic system of in lysosomes. Free cholesterol has a number of potential
metabolic fates, including esterification by acyl CoA:LDL R–deficient mice with bone marrow cells lacking
CXCR2, one two high-affinity receptors for IL-8 and cholesterol acyltransferase-1 (ACAT-1) and storage in
the lipid droplets that characterize foam cells. Choles-other CXC chemokines, resulted in significantly less ath-
Cell
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terol esters within these lipid droplets can in turn be cleared, suggesting a probable explanation for the ex-
hydrolyzed by hormone-sensitive lipase, generating free tremely low HDL cholesterol levels in Tangier patients.
cholesterol for incorporation into membranes and trans- Variability in ABC A1 expression and function due to
port out of the cell. Membrane incorporation of excess more subtle mutations may account for at least some
cholesterol inhibits the proteolytic activation of the of the variability of HDL levels in human populations.
SREBP transcription factors required for cholesterol Once the free cholesterol has been taken up from pe-
biosynthesis and LDL receptor expression (Brown and ripheral cells by HDL, it is esterified to cholesterol esters
Goldstein, 1999). While this prevents further accumula- by lecithin-cholesterol acyltransferase (LCAT). HDL can
tion of cholesterol via these pathways, it does not alter subsequently exchange cholesterol esters for triglycer-
cholesterol uptake via scavenger receptors or via ides carried by other lipoproteins via cholesterol ester
phagocytic mechanisms. Thus, mechanisms mediating transfer protein (CETP). Alternatively, HDL can selec-
cholesterol efflux are critical for maintenance of choles- tively deliver cholesterol esters to the liver for excretion
terol homeostasis in the macrophage. Disruption of by binding to the HDL receptor SR-B1. The physiologic
ACAT-1 results in marked systemic abnormalities in lipid importance of the SR-B1 receptor for reverse choles-
homeostasis in hypercholesterolemic apo E–deficient terol transport is suggested by the findings that hyper-
and LDL-R-deficient mice, leading to extensive deposi- cholesterolemic mice homozygous for a hypomorphic
tion of free cholesterol in skin and brain (Accad et al., SR-B1 allele develop increased atherosclerosis, while
2000; Yagu et al., 2000). ACAT-1 deficiency did not pre- mice that overexpress SR-B1 exhibit reduced athero-
vent development of atherosclerosis in these models, sclerosis (Huszar et al., 2000; Kozarsky et al., 2000).
but reduced the lipid and macrophage content of le-
sions. Although these alterations could result in more Lesion Progression and Immunologic Responses
stable lesions, the systemic lipid abnormalities observed The transition from the relatively simple fatty streak to
in ACAT-1-deficient mice suggest that therapeutic inhi- the more complex lesion is characterized by the immi-
bition of ACAT-1 could have detrimental effects. gration of smooth muscle cells from the medial layer of
The macrophage has two potential mechanisms for the artery wall past the internal elastic lamina and into
disposing of excess cholesterol: enzymatic modification the intimal, or subendothelial, space (Figure 3). Intimal
to more soluble forms and efflux via membrane trans- smooth muscle cells may proliferate and take up modi-
porters. The enzyme cholesterol 27 hydroxylase is ex- fied lipoproteins, contributing to foam cell formation,
pressed in macrophages at relatively high levels and and synthesize extracellular matrix proteins that lead to
could potentially play a role in cholesterol excretion by the development of the fibrous cap (Ross, 1999;
converting it to the more soluble 27-OH-cholesterol Steinberg and Witztum, 1999; Paulsson et al., 2000).
(Bjorkhem, 1992). The major mechanism for cholesterol This phase of lesion development is influenced by inter-
efflux, however, is likely to be via membrane transport- actions between monocyte/macrophages and T cells
ers, with HDL serving as the primary extracellular ac- that result in a broad range of cellular and humoral re-
ceptor. This role of HDL is thought to be critical for sponses and the acquisition of many features of a
physiologic “reverse cholesterol transport” and to at
chronic inflammatory state. Significant cross talk ap-
least partially explain why risk of atherosclerosis is in-
pears to occur among the cellular elements of devel-
versely correlated with HDL cholesterol levels (Tall et
oping lesions. Lesional T cells appear to be activated,
al., 2000). Although low HDL levels are a major risk factor
expressing both Th1 and Th2 cytokines (Hansson, 1997).for development of atherosclerosis, deletion of the apo
Similarly, macrophages, endothelial cells, and smoothA-I gene, which encodes the major protein component
muscle cells appear to be activated based on their ex-of HDL, is not sufficient to cause atherosclerosis in mice.
pression of MHC class II molecules and numerous in-However, apo A-I deficiency results in more severe ath-
flammatory products, such as TNFa, IL-6, and MCP-1erosclerosis in hypercholesterolemic mouse models,
(Figure 3).while adenovirus-mediated overexpression of apo A-I
Lymphocytes do not appear to be required for theis protective (Voyiaziakis et al., 1998; Benoit et al., 1999;
development of atherosclerosis. When apoE-deficientTangirala et al., 1999). There is also evidence that macro-
mice were crossed with RAG-1 recombinase-deficientphages may contribute directly to the availability of ex-
mice, which eliminates both T and B cell compartments,tracellular cholesterol acceptors through secretion of
and then fed cholesterol to achieve plasma cholesterolapo E (Linton et al., 1995), which is capable of contribut-
levels of 1600 mg/dl or greater, lesion formation wasing to the formation of HDL particles.
unaffected. However, if these double KO mice were fedA key insight into the molecular mechanisms respon-
a normal diet, so that cholesterol levels of “only” 600sible for cholesterol efflux resulted from studies of pa-
mg/dl were achieved, lesion formation was inhibited bytients with Tangier disease, which is characterized by
42% (Dansky et al., 1997). These data imply that onceextremely low levels of HDL and cholesterol accumula-
early lesions develop, immune responses modulate pro-tion in macrophages. Several different approaches led
gression. Immune responses appear to exert both ath-to the identification of null mutations in ABC A1, encod-
erogenic and antiatherogenic effects. Even a single im-ing a member of the ATP binding cassette family of
munomodulatory cytokine can exert both positive andtransporters, as the cause of Tangier disease (Bodzioch
negative effects. For example, the potent Th1-derivedet al., 1999; Brooks-Wilson et al., 1999; Lawn et al., 1999;
cytokine, interferong (IFNg), reduces scavenger receptorRust et al., 1999). Although mechanistic details remain to
expression on macrophages, decreases collagen syn-be defined, in vitro studies indicate that ABC A1 mediates
thesis, and inhibits smooth muscle cell proliferation, alltransport of cholesterol from cells to HDL acceptors. In
the absence of proper lipidation, HDL particles are rapidly potentially antiatherogenic effects. On the other hand,
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IFNg also stimulates macrophage production of proin- mice revealed that many recognized epitopes of oxi-
flammatory cytokines and increases expression of MHC dized phospholipids either as free lipids or as protein
class 2 molecules. Together, these effects of IFNg would adducts. These antibodies, mostly IgM, had the ability
be predicted to increase accumulation of macrophages to block the binding and degradation of oxLDL by mac-
within lesions and enhance their ability to present anti- rophages, suggesting that this epitope was a ligand for
gen to T cells. The net effect of IFNg in mice is athero- oxLDL uptake. Intriguingly, a genetic analysis of these
genic, as apo E–deficient mice lacking the IFNg receptor antibodies revealed that they were 100% homologous
(R0) exhibited significantly less atherosclerosis than to T15 natural antibodies to phosphorylcholine, which
control apo E–deficient mice (Gupta et al., 1997). Lesions provide optimal protection to mice against lethal infec-
were less cellular and had decreased collagen content. tion with S. pneumoniae (Shaw et al., 2000). Thus, these
Recent studies suggest that the interaction of CD40 evolutionarily conserved antibodies, which are present
ligand with its receptor promotes expression of a diverse even in mice raised in germ-free environments, were
set of atherogenic molecules by macrophages, smooth probably selected for their ability to bind to oxidized
muscle cells, and endothelial cells, including cytokines, membranes, and may have a protective role.
matrix metalloproteinases, adhesion molecules and tis- These observations suggest that it might be possible
sue factor (Mach et al., 1998a). Inhibition of CD40 signal- to modulate the development of atherosclerosis by im-
ing using genetic or immunologic approaches inhibited munization or other immune-based interventions. Elimi-
development of atherosclerosis in LDL receptor–defi- nation of T cells or immunization of experimental animals
cient mice and resulted in a more stable plaque pheno- with antigens that are homologous to endogenously ex-
type (Mach et al., 1998b; Lutgens et al., 1999). pressed proteins present in lesions, such as certain heat
Th2-derived cytokines also appear to have complex shock proteins, has been found to accelerate lesion
effects on lesion development. Interleukin-4 (IL-4) exerts formation. In contrast, intravenous administration of
a number of effects that are predicted to be antiathero- polyspecific immunoglobulin decreased lesion forma-
genic, including antagonistic effects on INFg activity in tion, as did hyperimmunization of hypercholesterolemic
macrophages and inhibition of Th1 cell function (Figure rabbit and murine models with homologous oxLDL
3). However, IL-4 is also a potent inducer of 15-LO, (Ho¨rkko¨ et al., 2000).
which promotes LDL oxidation and development of ath-
erosclerosis in mice. IL-10, which cross-regulates Th1 Plaque Stability
cells (Figure 3), has potent deactivating properties in Although advanced atherosclerotic lesions can lead to
macrophages and modulates several other cellular pro- ischemic symptoms as a result of progressive narrowing
cesses that may interfere with the development and of the vessel lumen, acute cardiovascular events that
stability of the atherosclerotic plaque. IL-10-deficient result in myocardial infarction and stroke are generally
mice exhibited a 3-fold increase in lipid accumulation, thought to result from plaque rupture and thrombosis
indicating an antiatherogenic role (Mallat et al., 1999; (Davies et al., 1993; Lee and Libby, 1997). Plaque rupture
Pinderski et al., 1999). Consistent with this, transgenic exposes plaque lipids and tissue factor to blood compo-
overexpression of IL10 in T cells using the human IL-2
nents, initiating the coagulation cascade, platelet adher-
promoter resulted in significant inhibition of lesion de-
ence, and thrombosis (Figure 4). Analysis of human ath-
velopment in C57BL/6J mice fed an atherogenic diet
erosclerosis suggests that the evolution of advanced
(Pinderski et al., 1999).
plaques may involve repetitive cycles of microhemorr-These observations indicate that immune activation is
hage and thrombosis. Plaque ruptures associated withongoing in atherosclerotic lesions. The most significant
acute myocardial infarction generally occur at the shoul-antigens responsible for immune activation are not
der regions of the plaque and are more likely to occurknown with certainty. Most attention has focused on
in lesions with thin fibrous caps, a relatively high concen-the role of bacterial and viral antigens, heat shock pro-
tration of lipid-filled macrophages within the shoulderteins, and neoepitopes (antigenic epitopes resulting
region, and large necrotic cores (Davies et al., 1993; Leefrom the formation of adducts between oxidized lipids
and Libby, 1997). Studies of human and animal modelsin oxLDL and apo B or arterial wall components). Sub-
of atherosclerosis suggest that programmed cell deathstantial evidence supports an important role for epitopes
plays a quantitatively important role in formation of theof oxLDL as dominant immunogens (Ho¨rkko¨ et al., 2000).
necrotic core (Bennet, 1999). Apoptosis of macrophagesThe ability of macrophages to function as antigen pre-
and vascular smooth muscle cells appears to result fromsenting cells (APCs) is undoubtedly related to the gener-
cell–cell interactions and the local cytokine environmentation of a variety of autoantibodies to oxidatively modi-
within the arterial wall, involving the actions of pro- andfied lipids and proteins that occurs with progressive
antiapoptotic proteins that include death receptors,atherosclerosis. Up to 10% of CD41 T cell clones from
proto-oncogenes, and tumor suppressor genes. Oxi-human carotid lesions proliferated specifically in re-
dized sterols present in oxLDL also appear to promotesponse to oxLDL in an HLA-DR-dependent manner
apoptosis and necrosis in lesions (Colles et al., 1996).(Hansson, 1997). There are now many reports in mice
In addition, the accumulation of apoptotic cells in theand humans of a strong correlation between autoanti-
lesions suggest that both increased production and de-body titers to epitopes of oxLDL and extent of athero-
creased disposal of such cells occur. Indeed the choles-sclerosis (reviewed in Ho¨rkko¨ et al., 2000) It is not yet
terol-loaded apoptotic cell may be akin to a trojan horse,clear whether such autoantibodies are simply markers
with macrophage uptake resulting in death of the ingest-for the extent of disease, or if they have any physiological
ing cell. The release of oxidized and insoluble lipid fromor pathophysiological role.
Cloning autoantibodies to oxLDL from apoE-deficient necrotic cells undoubtedly contributes to the formation
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Figure 4. Plaque Rupture and Thrombosis
Necrosis of macrophage and smooth muscle cell–derived foam cells leads to the formation of a necrotic core and accumulation of extracellular
cholesterol. Macrophage secretion of matrix metalloproteinases and neovascularization contribute to weakening of the fibrous plaque. Plaque
rupture exposes blood components to tissue factor, initiating coagulation, the recruitment of platelets, and the formation of a thrombus.
of the “gruel” characteristic of advanced lesions (Figure rhage or unstable angina (progressive episodes of tem-
porary cardiac ischemia due to transient thrombus4). Apoptosis of macrophages and smooth muscle cells
may not only be important in determining the ability of formation). Angiogenesis occurs in association with re-
modeling and protease activation in surrounding tissues,lesions to undergo regression, but may also influence
plaque stability, as such lipids in the necrotic core are suggesting that neovascularization could contribute to
plaque instability and rupture. Intimal or subendothelialsuggested to increase the potential for thrombosis.
Matrix metalloproteinases secreted by macrophages neovascularization has been observed in advanced ath-
erosclerotic lesions in apo E–deficient mice and treat-have been detected in regions of plaque rupture and
are suggested to influence plaque stability by degrading ment of these mice with the angiogenesis inhibitors en-
dostatin and TNP-470 significantly decreased lesionextracellular matrix proteins (Galis et al., 1994; Carmel-
iet, 2000). Thus, methods to alter the expression or activ- size (Moulton et al., 1999).
Although it has been difficult to establish animal mod-ities of metalloproteinases would be of potential clinical
benefit. To date, animal models in which plaque rupture els of spontaneous acute myocardial infarction (i.e., not
requiring direct interventions such as ligation of a coro-and the coagulation system reliably contribute to lesion
progression and acute thrombotic events have not been nary artery), the recent observation that it is possible to
reproducibly induce myocardial infarctions in mice withdeveloped. Variation in levels of several coagulation fac-
tors, including fibrinogen and factor VII, are associated combined LDL R and apo E deficiency by exposure to
mental stress or hypoxia (Caligiuri et al., 1999) shouldwith increased risk of cardiovascular disease (Table 1).
Extensive fibrin deposition is observed in most complex provide new opportunities for investigation of later
stages of lesion development. While myocardial infarc-human lesions (Figure 3), and decreased fibrinolytic ac-
tivity has been proposed to accelerate arterial athero- tions in this model do not appear to result from plaque
rupture, the ischemic consequences of transient hyp-genesis by facilitating thrombosis and fibrin deposition
within developing atherosclerotic lesions (Lee and oxia could be prevented by treatment with an endothelin
A receptor antagonist. These observations suggest anLibby, 1997). However, Apo E–deficient mice lacking
fibrinogen develop lesions that are similar in size and important role of endothelin-dependent vasoconstric-
tion in determining the extent of hypoxic injury that maycomplexity to control apo E–deficient mice (Xiao et al.,
1998). Similarly, LDL receptor–deficient mice lacking also be relevant to ischemic events resulting from coro-
nary thrombosis.plasminogen activator inhibitor-1 (PAI-1), which inhibits
the activator of plasminogen and thus should shift the
balance toward greater fibrin hydrolysis, also develop Toward New Therapies
As atherosclerosis is a chronic disease requiring lifetimetypical atherosclerotic lesions (Sjoland et al., 2000).
Neovascularization is prevalent in human atheroscle- preventive therapy, new antiatherogenic drugs should
meet the criteria of being safe, palatable, inexpensiverotic lesions associated with plaque rupture, hemor-
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Table 4. Potential Targets for Development of Small Molecule Inhibitors of Atherosclerosis
Target Drug Mechanism of Action
15-lipoxygenase Inhibitor Inhibition of LDL oxidation within the arterial wall
MTP Inhibitor Inhibition of VLDL assembly and secretion from liver
CCR2 Antagonist Inhibition of monocyte recruitment to vessel wall
Endothelin A Antagonist Inhibition of hypoxia-induced vasoconstriction
receptor
MMPs Inhibitor Prevention of plaque rupture
CETP Inhibitor Increased HDL cholesterol levels and reverse cholesterol transport
IkB kinase Inhibitor Inhibition of NFkB activation, resulting in decreased inflammatory responses
PPARa Agonist Decreased TG-rich lipoproteins, increased HDL, anti-inflammatory effects in
vessel wall
PPARg Selective modulator Decreased insulin resistance and anti-inflammatory effects in macrophage foam
cells
LXRa Selective modulator Decreased cholesterol absorption, increased hepatic cholesterol excretion and
increased reverse cholesterol transport from macrophage foam cells
RXR Selective modulator Activation of PPAR and LXR pathways. Current RXR ligands induce hypertriglycer-
idemia and central hypothyroidism
ERa,b Selective modulator Improved lipoprotein profiles and beneficial effects on arterial wall biology.
and of significant benefit beyond currently available atherogenic effects comparible to those observed in
animal models . Epidemiologic studies linking 15-LOtherapies. Small molecule–based approaches targeting
enzymes or signal-dependent transcription factors are expression levels or specific 15-LO polymorphisms to
risk of atherosclerosis could provide helpful informationthus much more likely to be of general clinical utility
than approaches requiring the delivery of genes or poly- along these lines. A challenge in carrying out interven-
tion studies in humans is the need to link a measurablepeptides. Multiple steps in the atherogenic process
could theoretically serve as the basis for intervention, parameter of the inhibitor’s activity with disease out-
come. In the case of statins, effectiveness of inhibitionincluding steps that control LDL levels and LDL oxida-
tion, monocyte recruitment, scavenger receptor expres- of HMG CoA reductase activity was readily assessed
by measurement of serum cholesterol levels, reductionssion and reverse cholesterol transport (Table 4). We con-
sider here selected examples of potential targets for new of which were highly correlated with reductions in ath-
erosclerotic complications. In contrast, the relevant siteclasses of antiatherogenic drugs that illustrate some
of the opportunities and practical challenges that lie of action of 15-LO inhibitors (as well as some of the
other potential targets listed in Table 4) is presumablyahead.
New approaches to lowering LDL cholesterol levels within the artery wall and not readily accessible for mea-
surement of inhibitory effects on LDL oxidation. In theand increasing HDL cholesterol levels remain attractive
avenues for development of novel classes of antiathero- 15-LO deficient mice, decreased excretion of isopros-
tanes, a breakdown product of arachidonic acid peroxi-genic drugs. Inhibitors of specific enzymes required for
lipoprotein synthesis and metabolism have already been dation, as well as autoantibodies to oxLDL correlated
strongly with the decreased extent of atherosclerosis,shown to exert beneficial effects on lipoprotein profiles
in animal models. For example, inhibitors of microsomal and could potentially be used to monitor inhibitor activity
in humans.triglyceride transfer protein (MTP), which is required for
the assembly of apo B–containing lipoproteins, have
been shown to reduce plasma LDL and VLDL cholesterol Nuclear Targets
Transcription factors that regulate cholesterol homeo-levels in rabbits (Wetterau et al., 1998). Overexpression
of human cholesterol ester transfer protein (CETP) which stasis, vascular wall biology, and/or inflammatory re-
sponses represent a potentially large class of thera-mediates exchange of cholesterol esters in HDL for tri-
glycerides in VLDL, increases atherosclerosis in apo peutic targets. Transcription factors represent more
complex targets for intervention than metabolic en-E–deficient and LDL receptor–deficient mice (Plump et
al., 1999). Consistent with this, CETP inhibitors have zymes because they are usually expressed in multiple
tissues and potentially regulate large numbers of genes.been shown to increase plasma HDL cholesterol levels,
decrease VLDL and LDL cholesterol, and inhibit devel- For example, members of the NFkB family coordinately
regulate gene clusters that control inflammatory re-opment of atherosclerosis in rabbits (Okamoto et al.,
2000). sponses and have been implicated in the development
of atherosclerosis (Thurberg and Collins, 1998). The de-Inhibitors of enzymes that play critical roles in LDL
oxidation are potentially novel classes of antiathero- velopment of inhibitors of NFkB, for example by tar-
geting the recently identified IkB kinases that are re-genic drugs that could work synergistically with choles-
terol lowering agents. 15-LO is an attractive target for quired for NFkB activation, will be of interest with
respect to their potential antiatherogenic properties.drug development, as genetic experiments in mice
clearly indicate that it is atherogenic and small molecule While such inhibitors are likely to be useful in acute
inflammation, clinical use in chronic disease settingsinhibitors of 15-LO have already been shown to reduce
development of atherosclerosis in rabbits (Sendobry et such as atherosclerosis may be more limited if therapeu-
tic effects come at the expense of compromised immuneal., 1997). Although 15-LO is expressed in human le-
sions, a critical unanswered question is whether it exerts function.
Cell
512
Several members of the nuclear receptor superfamily might inhibit inflammatory components of atherosclero-
have emerged as targets of drugs that have direct or sis. In addition, PPARg has recently been shown to in-
indirect effects on the development of atherosclerosis crease ABC A1 expression and cholesterol efflux in mac-
(Table 4). Estrogen receptors are important targets of rophages by a mechanism involving induction of LXRa
drugs for breast cancer and hormone replacement ther- (Chawla et al., 2001). Consistent with these observa-
apy and the impact of these agents on the cardiovascu- tions, PPARg agonists exert potent antiatherogenic ef-
lar system is an important consideration in their clinical fects in LDL R2/2 mice (Li et al., 2000), and reconstitution
use (Roe et al., 2000). Estrogens exert a number of pro- of the hematopoietic system of LDL R2/2 mice with
tective effects on lipoprotein profiles and the vascular PPARg2/2 bone marrow progenitor cells results in in-
wall, effects that are lost following menopause. Selective creased atherosclerosis compared to LDL R2/2 mice
estrogen receptor modulators (SERMs), including ta- reconstituted with wild-type progenitor cells (Chawla et
moxifen and raloxifene, have been developed that exert al., 2001). Because TZDs are now widely used in diabetic
proestrogenic effects in some tissues and antiestro- patients, who are at high risk for developing complica-
genic effects in others. Studies of postmenopausal tions of atherosclerosis, these observations have impor-
women given tamoxifen as adjuvant therapy after opera- tant clinical implications. The therapeutic benefits of
ble breast cancer found a significant decrease in myo- future generations of PPARg ligands in patients with
cardial infarction and tamoxifen has been shown to dra- type 2 diabetes mellitus could presumably be greatly
matically reduce cholesterol levels and development of enhanced by selecting compounds that retain insulin-
atherosclerosis in apo E–deficient mice (Reckless et al., sensitizing activities and are optimized for their antiath-
1997 and references therein). The selective effects of erogenic activities. The use of microarrays to assess
these ligands have been linked to their ability to recruit genome-wide responses of adipocytes, muscle cells
specific nuclear receptor coactivators and corepressors and macrophages to structurally distinct PPARg ligands
that exhibit tissue-specific patterns of expression and should be useful in selecting candidates that have these
that appear to integrate the activities of nuclear recep- properties for testing in vivo.
tors with other transcription factors in a promoter-spe- LXRs have more recently emerged as transcription
cific manner (Glass and Rosenfeld, 2000). The ability to factors that function in concert with SREBPs to regulate
selectively modulate the biological actions of the estro- cholesterol homeostasis (Repa et al., 2000a). While ele-
gen receptor with structurally distinct ligands suggests vated cellular levels of cholesterol and oxysterols sup-
that it will be possible to differentially modulate the activ- press the transcription of SREBP target genes, they
ities of other members of the nuclear receptor family. stimulate transcription of LXR target genes. LXR target
The peroxisome proliferator-activated receptor sub- genes include the 7a-hydroxylase gene in rodents,
family (PPARa, g, and d) also appears to play metabolic which encodes an enzyme catalyzing the rate-limiting
and immunologic roles that influence development of step required for bile acid synthesis and thus cholesterol
atherosclerosis (Fruchart et al., 1999). PPARa regulates excretion from liver. In addition, the ABC-A1 gene is
several aspects of fatty acid metabolism, including beta regulated in the intestine and in macrophages by LXRs
oxidation and uptake of fatty acids from triglyceride- (Costet et al., 2000; Repa et al., 2000b). Mice lacking
rich lipoproteins. Intriguingly, PPARa stimulates expres- LXRa develop massive hepatomegaly when placed on
sion of apoA-I and raises HDL levels in humans but a high cholesterol diet due to increased cholesterol ab-
not rodents due to differences in cis active regulatory sorption in the gut and impaired excretion from liver.
elements in the apoA-I promoter (Staels and Auwerx, Administration of potent RXR or LXR agonists to wild-
1998). The recognition that PPARa is the molecular tar- type mice substantially reduces cholesterol absorption,
get of the fibrate class of lipid-lowering drugs has facili- suggesting that this is a regulated step that is subject
tated the development of increasingly powerful agonists to pharmacologic intervention. However, LXR and RXR
that are in current clinical development. The observation
agonists also stimulate fatty acid biosynthesis in liver
that PPARa is expressed in endothelial and smooth
and an increase in circulating triglyceride levels by in-
muscle cells and that PPARa ligands can exert anti-
ducing the expression and activity of SREBP-1c (Repainflammatory effects in some settings (Staels et al., 1998)
et al., 2000a; Schultz et al., 2000). These observationsshould stimulate further efforts to evaluate their effects
suggest that it may be necessary to develop selectiveon the development of atherosclerosis.
modulators of RXRs and LXRs if they are to becomePPARg regulates fat cell development and glucose
useful targets of therapeutic intervention.homeostasis and is the molecular target of the thiazoli-
dinedione (TZD) class of insulin sensitizers used in the
Identification and Validation of Newtreatment of type 2 diabetes mellitus (Spiegelman,
Atherosclerosis Susceptibility Genes1998). Recent studies indicate that PPARg is also highly
Although atherosclerosis has long been the subject ofexpressed in macrophage foam cells and exerts both
intensive epidemiologic and pathophysiologic investi-pro- and antiatherogenic effects on macrophage gene
gation, there is considerable evidence that quantitativelyexpression (Jiang et al., 1998; Nagy et al., 1998; Ricote
important determinants of disease susceptibility remainet al., 1998a, 1998b; Tontonoz et al., 1998). On the one
to be identified (Hennekens, 1998). Family history ofhand, treatment of macrophages with TZDs has been
heart disease remains an important risk factor after re-shown to increase expression of the scavenger receptor
moving other previously identified independent factors,CD36, suggesting that these drugs might promote foam
implying additional genetic factors. In mice, atheroscle-cell formation. On the other hand, TZDs have been
rosis susceptibility varies dramatically in different strainshown to inhibit expression of TNFa, gelatinase B, and
other inflammatory mediators, suggesting that they backgrounds (Dansky et al., 1999). The majority of this
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variation cannot as yet be attributed to changes in Regular exercise, a healthy diet and management of
known risk factors, such as lipoprotein levels, again established risk factors such as hypercholesterolemia
suggesting yet to be discovered modifying genes. with available methods is accomplishing a great deal in
Studies of rare Mendelian disorders such as familial the prevention of atherosclerosis. For many individuals,
hypercholesterolemia and Tangier disease should con- however, these measures are not enough. The combina-
tinue to lead to the identification of genes that influence tion of robust animal models, emerging genomic and
the development of atherosclerosis. The recent discov- proteomic technologies, and the dividends of genome
ery of mutations in the ABC-A1 gene as the cause of sequencing efforts suggest that the stage is set for an
low HDL levels in Tangier patients provides a case in accelerated pace of discovery of the mechanisms con-
point. However, most common forms of atherosclerosis tributing to the pathogenesis of atherosclerosis and of
are multifactorial in origin and pure genetic approaches the development of powerful new antiatherogenic
have been less successful in pinning down significant drugs.
determinants of risk (Risch, 2000). For example, the ma-
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